391 related articles for article (PubMed ID: 31836452)
1. Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions.
Yadav J; Paragas E; Korzekwa K; Nagar S
Pharmacol Ther; 2020 Feb; 206():107449. PubMed ID: 31836452
[TBL] [Abstract][Full Text] [Related]
2. A numerical method for analysis of in vitro time-dependent inhibition data. Part 2. Application to experimental data.
Korzekwa K; Tweedie D; Argikar UA; Whitcher-Johnstone A; Bell L; Bickford S; Nagar S
Drug Metab Dispos; 2014 Sep; 42(9):1587-95. PubMed ID: 24939653
[TBL] [Abstract][Full Text] [Related]
3. A numerical method for analysis of in vitro time-dependent inhibition data. Part 1. Theoretical considerations.
Nagar S; Jones JP; Korzekwa K
Drug Metab Dispos; 2014 Sep; 42(9):1575-86. PubMed ID: 24939654
[TBL] [Abstract][Full Text] [Related]
4. Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.
Yadav J; Korzekwa K; Nagar S
Mol Pharm; 2018 May; 15(5):1979-1995. PubMed ID: 29608318
[TBL] [Abstract][Full Text] [Related]
5. Dynamic and Static Simulations of Fluvoxamine-Perpetrated Drug-Drug Interactions Using Multiple Cytochrome P450 Inhibition Modeling, and Determination of Perpetrator-Specific CYP Isoform Inhibition Constants and Fractional CYP Isoform Contributions to Victim Clearance.
Iga K
J Pharm Sci; 2016 Mar; 105(3):1307-17. PubMed ID: 26886336
[TBL] [Abstract][Full Text] [Related]
6. Atypical Michaelis-Menten kinetics in cytochrome P450 enzymes: A focus on substrate inhibition.
Leow JWH; Chan ECY
Biochem Pharmacol; 2019 Nov; 169():113615. PubMed ID: 31445022
[TBL] [Abstract][Full Text] [Related]
7. Cocktail-substrate approach-based high-throughput assay for evaluation of direct and time-dependent inhibition of multiple cytochrome P450 isoforms.
Kozakai K; Yamada Y; Oshikata M; Kawase T; Suzuki E; Haramaki Y; Taniguchi H
Drug Metab Pharmacokinet; 2014; 29(2):198-207. PubMed ID: 24172718
[TBL] [Abstract][Full Text] [Related]
8. The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition.
VandenBrink BM; Isoherranen N
Curr Opin Drug Discov Devel; 2010 Jan; 13(1):66-77. PubMed ID: 20047147
[TBL] [Abstract][Full Text] [Related]
9. High-throughput cytochrome P450 loss and metabolic intermediate complex assays to aid in designing out of CYP3A inactivation.
Russell DA; Cerny MA
Methods Enzymol; 2023; 690():341-368. PubMed ID: 37858534
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of an in vitro, seven-in-one human cytochrome P450 assay for evaluation of both direct and time-dependent inhibition.
Dahlinger D; Duechting S; Nuecken D; Sydow K; Fuhr U; Frechen S
J Pharmacol Toxicol Methods; 2016; 77():66-75. PubMed ID: 26528794
[TBL] [Abstract][Full Text] [Related]
11. Enzyme kinetics for clinically relevant CYP inhibition.
Zhang ZY; Wong YN
Curr Drug Metab; 2005 Jun; 6(3):241-57. PubMed ID: 15975042
[TBL] [Abstract][Full Text] [Related]
12. In Vitro Assessment of Potential for CYP-Inhibition-Based Drug-Drug Interaction Between Vonoprazan and Clopidogrel.
Nishihara M; Yamasaki H; Czerniak R; Jenkins H
Eur J Drug Metab Pharmacokinet; 2019 Apr; 44(2):217-227. PubMed ID: 30361928
[TBL] [Abstract][Full Text] [Related]
13. Translational aspects of cytochrome P450-mediated drug-drug interactions: A case study with clopidogrel.
Tornio A; Filppula AM; Backman JT
Basic Clin Pharmacol Toxicol; 2022 Jan; 130 Suppl 1():48-59. PubMed ID: 34410044
[TBL] [Abstract][Full Text] [Related]
14. The current status of time dependent CYP inhibition assay and in silico drug-drug interaction predictions.
Yan Z; Caldwell GW
Curr Top Med Chem; 2012; 12(11):1291-7. PubMed ID: 22571791
[TBL] [Abstract][Full Text] [Related]
15. Non-Michaelis-Menten kinetics in cytochrome P450-catalyzed reactions.
Atkins WM
Annu Rev Pharmacol Toxicol; 2005; 45():291-310. PubMed ID: 15832445
[TBL] [Abstract][Full Text] [Related]
16. Inhibition and induction of cytochrome P450 and the clinical implications.
Lin JH; Lu AY
Clin Pharmacokinet; 1998 Nov; 35(5):361-90. PubMed ID: 9839089
[TBL] [Abstract][Full Text] [Related]
17. Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction.
Kenny JR; Mukadam S; Zhang C; Tay S; Collins C; Galetin A; Khojasteh SC
Pharm Res; 2012 Jul; 29(7):1960-76. PubMed ID: 22415140
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 time-dependent inhibition and induction: advances in assays, risk analysis and modelling.
Riley RJ; Wilson CE
Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):557-72. PubMed ID: 25659570
[TBL] [Abstract][Full Text] [Related]
19. Prediction of drug-drug interactions arising from mechanism-based inactivation: key input parameters and impact on risk assessment.
Wong SG
Curr Drug Metab; 2011 Nov; 12(9):871-90. PubMed ID: 21619522
[TBL] [Abstract][Full Text] [Related]
20. Drug-drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation.
Venkatakrishnan K; Obach RS
Curr Drug Metab; 2007 Jun; 8(5):449-62. PubMed ID: 17584016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
